Država: Kanada
Jezik: angleščina
Source: Health Canada
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE
AURO PHARMA INC
N04BC05
PRAMIPEXOLE
0.125MG
TABLET
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE 0.125MG
ORAL
100
Prescription
NONERGOT-DERIVATIVE DOPAMINE RECEPTOR AGONISTS
Active ingredient group (AIG) number: 0152169005; AHFS:
CANCELLED POST MARKET
2016-11-29
Page 1 of 45 PRODUCT MONOGRAPH PR AURO-PRAMIPEXOLE Pramipexole Dihydrochloride Tablets 0.125 mg, 0.25 mg, 0.5 mg, 1.0 mg & 1.5 mg pramipexole dihydrochloride monohydrate Antiparkinsonian agent / Dopamine Agonist AURO PHARMA INC. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8 CANADA Submission control No.: 165933 Date of Preparation: April 23, 2014 Page 2 of 45 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................3 SUMMARY PRODUCT INFORMATION ....................................................................3 INDICATIONS AND CLINICAL USE..........................................................................3 CONTRAINDICATIONS .....................................................................................................3 WARNINGS AND PRECAUTIONS……………….………………………………............4 ADVERSE REACTIONS .....................................................................................................9 DRUG INTERACTIONS ...................................................................................................14 DOSAGE AND ADMINISTRATION ...............................................................................17 OVERDOSAGE .................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY..............................................................19 STORAGE AND STABILITY ...........................................................................................23 SPECIAL HANDLING INSTRUCTIONS ........................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING ..............................................23 PART II: SCIENTIFIC INFORMATION .............................................................................25 PHARMACEUTICAL INFORMATION ...........................................................................25 CLINICAL TRIALS ................... Preberite celoten dokument